Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | VVOS | Common Stock | Purchase | $16.2K | +8K | +51.61% | $2.03* | 23.5K | May 31, 2022 | Direct | F1 |
transaction | VVOS | Common Stock | Purchase | $7.32K | +4K | +17.02% | $1.83* | 27.5K | Jun 1, 2022 | Direct | |
holding | VVOS | Common Stock | 1.74M | May 31, 2022 | See footnote | F2 |
Id | Content |
---|---|
F1 | The price reported in Column 4 is a weighted average price. These shares were purchased in four separate transactions ranging from $2.02 to $2.035 on May 31, 2022. The reporting person undertakes to provide to Vivos Therapeutics, Inc., any security holder of Vivos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. |
F2 | Shares held by Coronado V Partners, LLC, of which the reporting person is a member and manager. |